Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + cisplatin + s-1
- Development stage
- Unknown
- Lead developer
- Taiho Pharmaceutical
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Gemcitabine + cisplatin + S-1 is a combination chemotherapy regimen primarily investigated for the treatment of advanced biliary tract cancer. Gemcitabine is a nucleoside analog that inhibits DNA synthesis by incorporating into DNA and inhibiting ribonucleotide reductase, leading to apoptosis in rapidly dividing cells[6]. Cisplatin is a platinum-based chemotherapeutic agent that forms DNA crosslinks and induces apoptosis. S-1 is an oral fluoropyrimidine derivative combining tegafur (a prodrug of 5-fluorouracil), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase), and oteracil (which reduces gastrointestinal toxicity). The triplet regimen aims to enhance antitumor efficacy compared to doublet regimens. Clinical trials have shown promising activity in advanced biliary tract cancer, with ongoing studies evaluating its safety and survival benefit[3][5][8].
- Brand names
- TeysunoGemzarPlatinol
- Other names
- GCS regimen
02
Targets
DNARRM1TS (Thymidylate synthase)
Beyond the preview
Go deeper on gemcitabine + cisplatin + s-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + cisplatin + s-1.